EnteroBiotix, an Aberdeen, Scotland, UK-based clinical stage microbiome therapeutics company, raised £2m in additional seed funding.
The round was led by Equity Gap with participation from the Scottish Investment Bank (the investment arm of Scottish Enterprise), the University of Aberdeen and the Bank Workers Charity, Barwell Plc, Gabriel, Syndicate Room, Fund Twenty8, NCIMB Limited and SIS Ventures.
The company intends to use the funds for international expansion following the opening of a new office in Boston, US.
Led by Dr James McIlroy MBChB, Founder and President, EnteroBiotix leverages the gut microbiome to develop novel medicinal products that restore health and prevent disease, with a specific focus on drug-resistant bacterial infections and gastrointestinal conditions. The company is using its MHRA-licensed platform capabilities, industry experience and patent pending technology to advance three core product portfolios that build on the science of the medical treatment known as faecal microbiota transplantation (FMT).
EnteroBiotix has established a UK/EU wide service to supply minimally manipulated microbiota products on a named patient basis under an MHRA manufacturers “specials” license.
It has also launched a strategic collaboration with the University of Glasgow to support translational research focused on identifying and evaluating precision antimicrobials that the company will combine with its whole ecosystem therapeutics to create an entirely novel medicinal product. The collaboration is supported by the Medical Research Council (MRC) Confidence in Concept (CiC) scheme.
The new office in Cambridge, Massachusetts is supporting EnteroBiotix’s operations and business development activities in the US.